Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 33 of 81 for:    acalabrutinib

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04075292
Recruitment Status : Recruiting
First Posted : August 30, 2019
Last Update Posted : July 20, 2020
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Condition or disease Intervention/treatment Phase
Untreated Chronic Lymphocytic Leukemia Drug: Acalabrutinib Drug: Rituximab Drug: Chlorambucil Phase 3

Detailed Description:
Patients be randomized in a 1:1 ratio into 2 arms to receive either acalabrutinib monotherapy (Arm A) or rituximab in combination with chlorambucil (Arm B). The primary objective of this study is to compare the efficacy of acalabrutinib relative to chlorambucil plus rituximab in subjects with previously untreated chronic lymphocytic leukemia without del(17p) or TP53 mutation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib Versus Chlorambucil Plus Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Actual Study Start Date : January 20, 2020
Estimated Primary Completion Date : February 8, 2024
Estimated Study Completion Date : February 8, 2024


Arm Intervention/treatment
Experimental: Acalabrutinib
Acalabrutinib will be orally administered until disease progression or unacceptable toxicity
Drug: Acalabrutinib
acalabrutinib 100 mg twice daily orally

Active Comparator: Rituximab and Chlorambucil
Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles
Drug: Rituximab
Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)

Drug: Chlorambucil
Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6




Primary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: approximately 50 months ]
    Progression free survival is defined as time from randomization until progression or death due to any cause (whichever occurs first)


Secondary Outcome Measures :
  1. Objective response rate [ Time Frame: approximately 50 months ]
  2. Duration of response [ Time Frame: approximately 50 months ]
  3. Time to next treatment [ Time Frame: approximately 50 months ]
  4. Overall survival [ Time Frame: approximately 50 months ]
  5. Minimal residual disease negativity rate [ Time Frame: approximately 50 months ]

Other Outcome Measures:
  1. Incidence of adverse events [ Time Frame: approximately 50 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women: (a) ≥65 years of age OR (b) >18 and <65 years of age, provided that they meet at least one of the following criteria: (i) Creatinine clearance 30 to 69 mL/min using the Cockcroft-Gault equation (iwCLL guidelines) (ii) A score higher than 6 on the Cumulative Illness Rating Score-Geriatric (CIRS G)
  • ECOG performance status of 0, 1, or 2
  • Diagnosis of CLL that meets published diagnostic criteria (Hallek 2018)
  • Active disease per IWCLL 2018 criteria that requires treatment
  • Adequate bone marrow function
  • Adequate renal and hepatic function

Exclusion Criteria:

  • Known detected del(17p) or TP53 mutation
  • Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (eg, Richter's transformation, PLL, or diffuse large B cell lymphoma [DLBCL]), or central nervous system (CNS) involvement by leukemia
  • History of prior malignancy except for the following: (a) Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study (b) Other cancers not specified above which have been curatively treated by surgery and/or radiation therapy from which subject is disease-free for ≥3 years without further treatment
  • Significant cardiovascular disease
  • Known history of infection with human immunodeficiency virus (HIV)
  • Serologic status reflecting active hepatitis B or C infection
  • Any active systemic infection (eg, bacterial, viral, or fungal infection) requiring systemic treatment
  • History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
  • Major surgical procedure within 30 days of first dose of study drug
  • Any prior CLL-specific therapies
  • Corticosteroid use >20 mg within 1 week before first dose of study drug, except as indicated for other medical conditions
  • Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists
  • For women only: breastfeeding or pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04075292


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Layout table for location information
China
Research Site Not yet recruiting
Beijing, China, 100191
Research Site Not yet recruiting
Changchun, China, 130021
Research Site Not yet recruiting
Changsha, China, 410013
Research Site Not yet recruiting
Changzhou, China, 272100
Research Site Not yet recruiting
Fuzhou, China, 350001
Research Site Not yet recruiting
Guangzhou, China, 510100
Research Site Not yet recruiting
Guangzhou, China, 510515
Research Site Not yet recruiting
Hangzhou, China, 310003
Research Site Not yet recruiting
Hefei, China, 230001
Research Site Not yet recruiting
Hefei, China, 230031
Research Site Not yet recruiting
Lanzhou, China, 730030
Research Site Not yet recruiting
Nanjing, China, 210029
Research Site Not yet recruiting
Qingdao, China, 266003
Research Site Not yet recruiting
Shanghai, China, 200025
Research Site Not yet recruiting
Shanghai, China, 200040
Research Site Not yet recruiting
Shenyang, China, 110001
Research Site Not yet recruiting
Shijiazhuang, China, 050020
Research Site Not yet recruiting
Suzhou, China, 215006
Research Site Not yet recruiting
Tianjin, China, 300020
Research Site Not yet recruiting
Zhengzhou, China, 450052
Philippines
Research Site Not yet recruiting
Baguio City, Philippines, 2600
Research Site Not yet recruiting
Cebu, Philippines, 6000
Research Site Not yet recruiting
Davao City, Philippines, 8000
Research Site Not yet recruiting
Legazpi City, Philippines, 4500
Research Site Not yet recruiting
Makati, Philippines, 1229
Research Site Not yet recruiting
Manila, Philippines, 1000
Research Site Not yet recruiting
Quezon City, Philippines, 1112
Taiwan
Research Site Recruiting
Kaohsiung, Taiwan, 833
Research Site Not yet recruiting
Taichung, Taiwan, 404
Research Site Recruiting
Tainan, Taiwan, 704
Research Site Not yet recruiting
Taipei, Taiwan, 10002
Research Site Recruiting
Taipei, Taiwan, 11217
Research Site Recruiting
Taoyuan City, Taiwan, 333
Thailand
Research Site Recruiting
Bangkok, Thailand, 10330
Research Site Recruiting
Bangkok, Thailand, 10400
Research Site Not yet recruiting
Bangkok, Thailand, 10400
Research Site Recruiting
Bangkok, Thailand, 10700
Research Site Recruiting
Chiang Mai, Thailand, 50200
Research Site Recruiting
Hat Yai, Thailand, 90110
Research Site Recruiting
Khon Kaen, Thailand, 40002
Vietnam
Research Site Not yet recruiting
Hanoi, Vietnam, 100000
Research Site Not yet recruiting
Ho Chi Minh city, Vietnam
Research Site Not yet recruiting
Ho Chi Minh, Vietnam, 700000
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Lugui Qiu, MD Chinese Academy of Medical Science Affiliated Hospital of Hematology
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT04075292    
Other Study ID Numbers: D822BC00001
First Posted: August 30, 2019    Key Record Dates
Last Update Posted: July 20, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
Chronic Lymphocytic Leukemia
Acalabrutinib
Progression-free Survival
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Rituximab
Chlorambucil
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action